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ABSTRACT
Strains of Enterobacteriaceae producing an extended spectrum b-lactamase have become a concern in
medical bacteriology as regards both antimicrobial treatment and infection control in hospitals.
Extended-spectrum b-lactamase (ESBL) detection tests should accurately discriminate between bacteria
producing these enzymes and those with other mechanisms of resistance to b-lactams, e.g., broad-
spectrum b-lactamases, inhibitor-resistant b-lactamases and cephalosporinase overproduction. Several
phenotypic detection tests, based on the synergy between a third-generation cephalosporin and
clavulanate, have been designed: the double-disk synergy test (DDST), ESBL Etests, and the combination
disk method. These tests often need to be reﬁned in order for them to detect an ESBL in some bacterial
strains, such as those that also overproduce a cephalosporinase. The sensitivity of the DDST can be
improved by reducing the distance between the disks of cephalosporins and clavulanate. The use of
cefepime, a fourth-generation cephalosporin that is less rapidly inactivated by cephalosporinase than by
ESBL, improves the detection of synergy with clavulanate when there is simultaneous stable
hyperproduction of a cephalosporinase; alternatively, the cephalosporinase can be inactivated by
performing phenotypic tests on a cloxacillin-containing agar. Some b-lactamases can hydrolyse both
third-generation cephalosporins and carbapenems, such as the metallo-b-lactamases, which are not
inhibited by clavulanate, but rather by EDTA. The production of an ESBL masked by a metallo-
b-lactamase can be detected by means of double inhibition by EDTA and clavulanate. Since extended-
spectrum Ambler class D oxacillinases are weakly inhibited by clavulanate and not inhibited by EDTA,
their detection is difﬁcult in the routine laboratory.
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INTRODUCTION
Since the ﬁrst reports of strains of Klebsiella spp.
resistant to third-generation cephalosporins [1]
and the ﬁrst descriptions of the mechanism of
resistance involved [2–5], the epidemiological suc-
cess of Enterobacteriaceae producing extended-
spectrum b-lactamases (ESBLs) has become a
concern in the ﬁeld of medical bacteriology [6–9].
Because of the risk of treatment failure with
third-generation cephalosporins or with aztreo-
nam [10–12], it is often recommended to report
ESBL-producing Enterobacteriaceae as resistant to
these antibiotics, even when the strains appear
susceptible according to standard breakpoints
(http://www.sfm.asso.fr/). Moreover, the detec-
tion of ESBL-producing strains may prompt the
implementation of isolation procedures to pre-
vent cross-transmission to other patients. The
ESBL phenotypic detection tests, therefore, have
to accurately discriminate between ESBL-produc-
ing strains and those having other acquired
mechanisms of resistance to b-lactam antibiotics.
Among Enterobacteriaceae, the three main non-
ESBL resistance patterns are those caused by: (a)
broad-spectrum b-lactamases (TEM-1, TEM-2,
SHV-1, etc.), which confer high-level resistance
to amino- and carboxy-penicillins and are char-
acterised by a marked synergy between these
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antibiotics and b-lactamase inhibitors such as
clavulanate or sulbactam; (b) inhibitor-resistant
b-lactamases (TEM derivatives), which confer
resistance to amino- and carboxy-penicillins, and
are characterised by anabsence of synergy between
these antibiotics and inhibitors, resulting in resis-
tance to the combinations amoxicillin–clavulanate,
ampicillin–sulbactam and ticarcillin–clavulanate;
and (c) cephalosporinase overproduction, which
confers resistance to amino- and carboxy-penicil-
lins, as well as to second- and third-generation
cephalosporins and aztreonam, and is character-
ised by a lack of synergy between these antibiotics
and inhibitors.
The main characteristics of ESBL-mediated
resistance in Enterobacteriaceae are: (a) the resis-
tance to amino- and carboxy-penicillins, as well as
to second-generation and one or several third-
and fourth-generation cephalosporins or aztreo-
nam; and (b) a synergy between these antibiotics
and b-lactamase inhibitors, particularly clavula-
nate. Resistance, at breakpoint, is not always
obvious to all third- or fourth-generation cepha-
losporins, whether based on disk-diffusion in
agar, MIC determination or automated systems
[13]. Since the 1980s, speciﬁc phenotypic tests
have therefore been developed to detect ESBL
production. All are based on the use of a third-
generation cephalosporin, usually cefotaxime or
ceftazidime, and a b-lactamase inhibitor, usually
clavulanate, and rely on the reduction of the MIC
of the former in the presence of the latter,
demonstrating synergy.
This review describes the phenotypic methods
for ESBL detection, illustrates the results obtained
at the bench and analyses their advantages and
limits.
DESCRIPTION OF THE ESBL
DETECTION TESTS
Double-disk synergy test
The ﬁrst test speciﬁcally designed to detect ESBL
production in Enterobacteriaceae was the double-
disk synergy test (DDST) [7]. It was initially
designed to differentiate between cefotaxime-
resistant strains, i.e., those overproducing cepha-
losporinase, and those producing ESBLs. The test
is performed on agar with a 30-lg disk of cefo-
taxime (and ⁄ or ceftriaxone and ⁄ or ceftazidime
and ⁄ or aztreonam) and a disk of amoxicillin–
clavulanate (containing 10 lg of clavulanate) posi-
tioned at a distance of 30 mm (centre to centre),
i.e., at the distance provided by several types of
disk-dispenser (Fig. 1). The test is considered as
positive when a decreased susceptibility to cefo-
taxime is combined with a clear-cut enhancement
of the inhibition zone of cefotaxime in front of the
clavulanate-containing disk, often resulting in a
characteristic shape-zone referred to as ‘cham-
pagne-cork’ or ‘keyhole’. Figs 2 and 3 give several
examples of positive DDSTs for different enzymes
and Enterobacteriaceae species. The DDST was
ﬁrst used in epidemiological studies to assess the
spread of ESBL-producing Enterobacteriaceae in
French hospitals [8,9]. It has been shown to work
well with a wide range of Enterobacteriaceae
species and ESBL types, and it is generally
regarded as a reliable method for the detection
of ESBLs, although it is sometimes necessary to
adjust the disk spacing. It is important to note that
reducing the distance between the clavulanate-
containing disk and the third-generation cephalo-
sporin disk (e.g., to 20 mm) signiﬁcantly improves
the test sensitivity [14,15]. Since the antibiotic
disks are routinely spaced 30 mm apart by several
types of marketed disk-dispenser, it is necessary,
when the result of the test is equivocal (i.e., clear
decrease in susceptibility to third-generation
cephalosporins without clear synergy), to perform
an additional test by arranging the disks by hand
with narrower distances (Fig. 4).
ESBL Etests
ESBL Etests have been developed in order to
quantify the synergy between extended-spectrum
Fig. 1. A positive double-disk synergy test as described in
the initial publication [7]. Cefotaxime (CTX) and amoxicil-
lin–clavulanate (AMC) disks are placed at a distance of
30 mm from one another. The inhibition zone is enhanced
between those two disks, indicating synergy between
cefotaxime and clavulanate.
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cephalosporins and clavulanate. The Etests called
CT ⁄CTL, TZ ⁄TZL and PM ⁄PML are two-sided
strips containing gradients of cefotaxime (CT), or
ceftazidime (TZ) or cefepime (PM), either alone
(at one end of the strip), or combined with
clavulanate 4 mg ⁄L (on the other end). The ESBL
test is considered as positive when the MIC value
of the tested drug is reduced by more than three
doubling dilution steps (MIC ratio ‡8) in the
presence of clavulanate [16]. The test is also
considered as positive when there is either: (a) a
rounded zone (phantom zone) just below the
lowest concentration of CTL, TZL or PML gradi-
ents, or (b) a deformation of the CT, TZ or PM
inhibition ellipse at the tapering end. The pres-
ence of a phantom zone or an ellipse deformation
indicates ESBL production. Interpreting results of
the ESBL Etest strips is delicate and requires
training. In a recent study, it has been reported
that laboratories may fail to interpret correctly the
inhibition ellipse in c. 30% of cases [17]. In
addition, ESBL detection by Etest may fail when
(a) (b)
(c)
(e)
(d)
Fig. 2. Double-disk synergy tests
for several SHV-derivative exte-
nded-spectrum b-lactamases in sev-
eral Enterobacteriaceae. Synergy
between cefotaxime (CTX), ceftazi-
dime (CAZ), aztreonam (ATM) or
cefepime (FEP), and clavulanate
(amoxicillin–clavulanate (AMC) or
ticarcillin–clavulanate (TCC)), is
indicated by arrows. (a) Escherichia
coli SHV-2. (b) Klebsiella pneumoniae
SHV-4. (c) Salmonella Enteritidis
SHV-12. (d) K. pneumoniae SHV-12.
(e) Enterobacter cloacae producing
inducible cephalosporinase and
SHV-12.
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the MIC values for cephalosporins fall outside the
range of MICs available on the test strip [18], as
will be shown below.
Combination disk method
Several manufacturers have developed ESBL
detection tests based on the combination disk
method. The principle of this method is to
measure the inhibition zone around a disk of
cephalosporin and around a disk of the same
cephalosporin plus clavulanate. Depending on
the disk type, a difference of ‡5 mm between the
two diameters (i.e., corresponding to a two-fold
dilution), or a zone expansion of 50% are consid-
ered as indicating ESBL production [19,20]. The
test is easy to perform and its interpretation is
straightforward. Sensitivity and speciﬁcity for this
method were ﬁrst reported to be 96% and 100%,
respectively [18]. Carter et al. [19] evaluated the
performance of the Oxoid cefpodoxime
10 ng ± 1 lg clavulanate combination disks to
distinguish ESBL producers from AmpC
overproducers and Klebsiella oxytoca isolates
(a) (b)
(c)
(e)
(d)
Fig. 3. Double-disk synergy tests
for TEM, CTX-M and PER
extended-spectrum b-lactamases.
Synergy between cefotaxime (CTX),
ceftazidime (CAZ), aztreonam
(ATM) or cefepime (FEP), and cla-
vulanate (amoxicillin–clavulanate
(AMC) or ticarcillin–clavulanate
(TCC)), is indicated by arrows. (a)
Citrobacter diversusTEM-3. (b)Serratia
marcescens producing inducible
cephalosporinase and CTX-M3. (c)
Escherichia coli CTX-M-15. (d) E. coli
CTX-M-27. (e)ProteusmirabilisPER-1.
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overexpressing K1 enzyme. The presence of cla-
vulanate enlarged the zone of inhibition by
‡5 mm for all 180 ESBL-producing organisms,
and by £1 mm for AmpC overproducers and
K. oxytoca isolates overexpressing K1 enzyme.
Automated method
The VITEK 2 ESBL test (bioMe´rieux, Marcy
l’Etoile, France) is based on the simultaneous
assessment of the antibacterial activity of
(a) (b)
(c)
(e)(d)
Fig. 4. Detection of extended-spec-
trum b-lactamase (ESBL) production
in an Enterobacter cloacae strain that
stably overproduces a cephalospo-
rinase, by combining several tests.
CTX, cefotaxime; CAZ, ceftazidime;
FEP, cefepime; AMC, amoxicillin–
clavulanate; TCC, ticarcillin–clavul-
anate. (a) Disk diffusion test on
conventional Mueller–Hinton (MH)
agar. No synergy is detected
between cefotaxime (CTX), ceftazi-
dime (CAZ) or cefepime (FEP) and a
clavulanate-containing disk (amoxi-
cillin–clavulanate (AMC) or ticarcil-
lin–clavulanate (TCC)). (b) Positive
disk synergy test (arrows) using
narrowed distances (<30 mm)
between the clavulanate-containing
disk (amoxicillin–clavulanate) and
the disks of third- or fourth-genera-
tion cephalosporins (cefotaxime or
cefepime). (c) Positive disk synergy
test (arrows) on cloxacillin-contain-
ing agar (200 mg ⁄L). (d) ESBL Etests
on conventional MH agar. CT,
cefotaxime; CTL, cefotaxime with
clavulanate 4 mg ⁄L; PM, cefepime;
PML, cefepime with clavulanate
4 mg ⁄L. All MICs are over range.
(e) Positive ESBL Etest on agar
containing cloxacillin (200 mg ⁄L).
MICs are: CT >16 mg ⁄L, CTL
>1 mg ⁄L, PM >16 mg ⁄L, PML
0.5 mg ⁄L.
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cefepime, cefotaxime and ceftazidime, measured
either alone or in the presence of clavulanate. This
test relies on card wells containing 1.0 mg ⁄L of
cefepime, or 0.5 mg ⁄L of cefotaxime or ceftazi-
dime, either alone or associated with 10 or
4 mg ⁄L of clavulanate, respectively. After inocu-
lation, cards are introduced into the VITEK 2
machine, and for each antibiotic tested, turbidity
is measured at regular intervals. The proportional
reduction of growth in wells containing a ceph-
alosporin combined with clavulanate is then
compared with that achieved by the cephalospo-
rin alone and is interpreted as ESBL-positive or -
negative through a computerised expert system
(Advanced Expert System).
The automated Phoenix ESBL test (Becton
Dickinson, Sparks, MD, USA) also relies on the
growth response to selected expanded-spectrum
cephalosporins. This test is composed of ﬁve
wells, each containing a cephalosporin alone or in
combination with clavulanic acid (cefpodoxime,
ceftazidime, ceftazidime with clavulanic acid,
cefotaxime with clavulanic acid and ceftriaxone
with clavulanic acid). In this system, the results
are also interpreted through a computerised
system.
Many studies have evaluated the ability of
automated systems to detect ESBL-producing En-
terobacteriaceae ([13]) and some of these studies
are summarised below. Sanders et al. [21] evalu-
ated the VITEK 2 automated system and the DDST
using well-characterised ESBL-producing strains
of Escherichia coli (n = 176) and Klebsiella pneumo-
niae (n = 157). The performance of both methods
was found to be similarly good, with sensitivity
and speciﬁcity values of 99.5% and 100% for the
VITEK vs. 98% and 99.5% for the DDST. More
recently, Schwaber et al. [22] assessed the perfor-
mance of the VITEK 2, using 40 ESBL-producing
clinical isolates of Enterobacter spp. This system
identiﬁed only 25 of these 40 isolates (62.5%) as
ESBL producers, indicating that the method is less
efﬁcient for AmpC-inducible species than for
E. coli and K. pneumoniae. Sanguinetti et al. [23]
evaluated the Phoenix automated test for ESBL
detection using 510 clinical isolates of Enterobac-
teriaceae, including 319 ESBL producers belonging
to a large range of species. Among these ESBL
producers, 59 belonged toAmpC-inducible species
such as Enterobacter aerogenes, Enterobacter cloacae,
Citrobacter freundii and Providencia stuartii. They
reported 100% sensitivity and 98.9% speciﬁcity.
An important and recent study by Wiegand
et al. [24] compared these two automated systems
with: (a) a third automated system (Microscan
WalkAway-96 System, Dade Behring); (b) the
DDST using four cephalosporin disks (cefotax-
ime, ceftazidime, cefpodoxime and cefpirome); (c)
the combination disk method using cefotaxime,
ceftazidime and cefpodoxime disks containing or
not containing clavulanic acid; and (d) the E-test
method. A collection of 144 Enterobacteriaceae
isolates (85 ESBL producers) was included in the
study. The main results are presented in Table 1.
It should be noted that for the Microscan system,
the ESBL detection was limited to E. coli and
Klebsiella spp. and that VITEK 2 was used with
the conventional cards and not with the ESBL-
speciﬁc cards containing cephalosporin–clavula-
nate combinations. The results of this study show
that the overall sensitivity was above 90% with
the Phoenix system and all agar diffusion meth-
ods, and reached 94% or more for the subgroup
E. coli and Klebsiella spp. For the subgroup pro-
ducing inducible AmpC enzyme (Enterobacter
spp., C. freundii and Serratia marcescens), the sen-
sitivity reached 90% or more with Phoenix,
VITEK 2 and the DDST. The overall speciﬁcity
Table 1. Sensitivity and speciﬁcity of phenotypic methods
for detection of extended-spectrum b-lactamase (ESBL)
production in 144 Enterobacteriaceae (85 ESBL-producing
strains) [24]
Species
studied Method
Sensitivity
(%)
Speciﬁcity
(%)
All species
(n = 144)
Phoenix 98.8 52.2
VITEK 2 85.9 78.0
MicroScan 83.5 72.9
DDST 94.1 81.4
CDM 92.9 96.6
ESBL Etests 94.1 84.7
Escherichia coli,
Klebsiella spp.
(n = 104)
Phoenix 100.0 51.5
VITEK 2 84.5 93.9
MicroScan 98.6 51.5
DDST 94.4 72.7
CDM 94.4 97.0
ESBL Etests 98.6 72.7
Enterobacter,
Citrobacter and
Serratia spp.
(n = 28)
Phoenix 90.0 33.3
VITEK 2 100.0 38.9
MicroScan 0.0 ND
DDST 90.0 100.0
CDM 80.0 100.0
ESBL Etests 60.0 100.0
DDST, double-disk synergy test; CDM, combination disk
method; ND, not determined.
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reached 90% only with the combination disk
method, whereas the speciﬁcity reached this level
with VITEK 2 for the subgroup E. coli and Klebsi-
ella spp., and with DDST and Etest for the
subgroup producing inducible AmpC. It should
be noted that for the AmpC-inducible subgroup,
the speciﬁcity of VITEK 2 and Phoenix was below
40%. Very recently, Thomson et al. [25] evaluated
VITEK 2 and Phoenix, both with ESBL-speciﬁc
cards, on 102 well-characterised strains of E. coli,
K. pneumoniae and K. oxytoca, including 76 ESBL
producers. Sensitivity and speciﬁcity for ESBL
detection were 96% and 81%, respectively for
Phoenix, and 89% and 85%, respectively for
VITEK 2.
Screening method
The CLSI recommends a two-step method, the
ﬁrst step being a screening test for reduced
susceptibility to more than one of the indicator
cephalosporins (cefotaxime, ceftriaxone, ceftazi-
dime, cefpodoxime and aztreonam). Reduced
susceptibility indicates a positive result. A sub-
sequent conﬁrmation of ESBL production is then
given by the demonstration of synergy between
ceftazidime or cefotaxime and clavulanate. The
presence of an ESBL is conﬁrmed in E. coli,
Proteus mirabilis, K. pneumoniae or K. oxytoca if:
(a) the MIC values in the presence of clavulanate
are reduced by at least three two-fold dilutions; or
(b) the diameter of the inhibition zone is increased
by at least 5 mm when the tested cephalosporin is
combined with clavulanate [26]. The major draw-
back of the CLSI guideline is the absence of
recommendations for the interpretation of ESBL
testing results for those species of Enterobacteri-
aceae that are also good AmpC producers, such as
C. freundii, Enterobacter spp., Morganella morganii,
P. stuartii, and Serratia spp.
Three-dimensional tests
Two types of three-dimensional tests, direct or
indirect, are proposed by Thomson and Sanders
[14]. The direct three-dimensional test is a mod-
iﬁcation of the disk-diffusion test that generates
data on both antimicrobial susceptibility of the
tested strain and substrate proﬁle of the b-lac-
tamase produced by this strain. In this test, the
studied organism is inoculated onto the surface of
an agar plate (inoculum with optical density of
0.5 McFarland) and then dispensed with a higher
inoculum (between 109 and 1010 cells ⁄mL) in a
circular slit cut in the agar so that the slit is ﬁlled.
Afterwards, antibiotic disks are placed on the
agar plate, 3 mm outside the strain-containing
slit. Enzymic inactivation of each antibiotic is
detected by inspection of the margin of the
inhibition zone in the vicinity of its intersection
with the strain-containing slit. Inactivation of the
antibiotic, as it diffuses through the slit, results in
a distortion or discontinuity in the expected
circular inhibition zone, or the production of
discrete colonies in the vicinity of the inoculated
slit.
The indirect three-dimensional test is a modi-
ﬁcation of the direct three-dimensional test, in
which the surface of the agar plate is inoculated
with a fully susceptible indicator strain
(ATCC 25922). With the exception of this modi-
ﬁcation, the method is the same as that described
for the direct three-dimensional test. This test is
used for the b-lactams that do not give an
inhibition zone by the direct test and for which
information on inactivation is therefore not pro-
vided. This test provides data on the substrate
proﬁle of the b-lactamase produced by the tested
strain. Of course, the indirect test does not
provide information on susceptibility of the tested
strain. Thomson and Sanders compared the com-
bination of the direct and the indirect three-
dimensional test and the DDST with 32 strains of
E. coli and K. pneumoniae, 28 of which produced
ESBL [14]. They reported detection rates of 93%
for the three-dimensional test and 82% for DDST.
It has to be noted that no strain overproducing a
cephalosporinase was included in this study.
COMBINING SEVERAL ESBL TESTS
AT THE BENCH
Adaptation of the DDST to detect an ESBL in
strains overproducing cephalosporinase
Several bacterial species (Enterobacter spp.,
C. freundii, M. morganii, P. stuartii, and S. marces-
cens) have inducible chromosomally encoded
AmpC cephalosporinase. Either inducibility or
stable overproduction of this enzyme, resulting
from mutation, can coexist with the production of
an acquired ESBL. When the AmpC b-lactamase
is inducible, a synergistic effect is detected as
easily as in E. coli and Klebsiella spp., as illustrated
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in Fig. 2e (E. cloacae SHV-12). In contrast, synergy
is often hidden when the AmpC b-lactamase is
stably overproduced. As shown in Fig. 4a, no
synergy is detected for this clinical strain of
E. cloacae producing an ESBL and stably overpro-
ducing AmpC b-lactamase.
Several modiﬁcations of the DDST may facili-
tate detection when the ESBL phenotype is hid-
den by a stably overproduced cephalosporinase
in this manner:
• Some cephalosporins, e.g., cefepime, are less
rapidly inactivated by AmpC cephalosporinas-
es than by ESBLs. In one study, cefepime was
used in a DDST approach for the detection of
ESBLs in Enterobacter spp. strains that also
stably overproduce a cephalosporinase. Tzelepi
et al. [15] reported a sensitivity of 16% only
when using cefotaxime, ceftriaxone, ceftazi-
dime and aztreonam disks (positive test with
at least one molecule). The use of cefepime
increased the sensitivity of the test to 61%when
the disk was placed at a standard distance
(30 mm) from the clavulanate-containing disk.
Sensitivity increased even more, to 90%, when
this distance was reduced to 20 mm.
• Performing the DDST on agar containing clox-
acillin (200 mg ⁄L) was shown long ago to
inhibit cephalosporinase activity [27] and has
been shown to enhance the ability of the test to
detect ESBL-producing Acinetobacter baumannii
[28] and Pseudomonas aeruginosa [29]. Two exam-
ples of ESBL detection on cloxacillin-containing
agar are illustrated in Fig. 5; for E. cloacae with
SHV-12 enzyme in Fig. 5a, b and for S. marces-
cens with TEM-19 in Fig. 5c, d.
• Narrowing the distance between the clavula-
nate-containing disk and the disks of third-
generation cephalosporins to <30 mm can also
enhance the detection of ESBLs in AmpC-
expressing species [30], as previously men-
tioned.
Combining several tests for ESBL detection
in strains resistant to third-generation
cephalosporins through cephalosporinase
stable overproduction.
Fig. 4 illustrates the different approaches that can
be applied at the bench to detect ESBL production
in a strain of E. cloacae that stably overproduces
(a) (b)
(c) (d)
Fig. 5. Extended-spectrum b-lacta-
mase detection by a double-disk
diffusion test on agar containing
cloxacillin (200 mg ⁄L) for clinical
isolates that stably overproduce a
cephalosporinase. Synergy between
cefotaxime (CTX), ceftazidime
(CAZ) or cefepime (FEP) and cla-
vulanate (amoxicillin–clavulanate
(AMC) or ticarcillin–clavulanate
(TCC)) is indicated by arrows. (a)
and (b) Enterobacter cloacae with
SHV-12 enzyme. (c) and (d) Serratia
marcescens with TEM-19. (a) and (c)
are on conventional Mueller–Hinton
agar. (b) and (d) are on cloxacillin-
containing agar.
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AmpC b-lactamase. The standard diffusion test
shown in Fig. 4a does not provide evidence of
ESBL production (no synergy between clavula-
nate and third-generation cephalosporins or even
cefepime). In contrast, synergy is unambiguously
detected when the distance between the cefepime
and clavulanate disks is reduced (<30 mm)
(Fig. 4b) or when the test is performed on clox-
acillin-containing plates (Fig. 4c). These examples
clearly illustrate the need to modify the standard
DDST method when dealing with cephalosporin-
ase overproducers. Combinations of these meth-
ods can further improve the detection of ESBLs.
For ESBL Etests, the use of cloxacillin-containing
media is recommended when the MIC values are
higher than those measurable on the strips. This is
(a) (b)
(c)
(e) (f)
(d)
Fig. 6. Combination of several tests
for extended-spectrum b-lactamase
(ESBL) detection in two Enterobacter
cloacae strains: one (EC1) stably
overproducing a cephalosporinase,
the other (EC2) stably overproduc-
ing a cephalosporinase and produc-
ing an ESBL. (a) Conventional disk
test with EC1; no synergy is de-
tected. (b) Conventional disk test
with EC2; no synergy is detected.
(c) ESBL Etests on Mueller–Hinton
(MH) agar with EC1; CT, cefotax-
ime; CTL, cefotaxime with clavula-
nate 4 mg ⁄L; PM, cefepime; PML,
cefepime with clavulanate 4 mg ⁄L.
MICs are: CT >16 mg ⁄L, CTL
>1 mg ⁄L, PM 4 mg ⁄L, PML
>4 mg ⁄L. (d) ESBL Etests on MH
agar with EC2. All MICs are over
range. (e) ESBL Etests on agar con-
taining cloxacillin (200 mg ⁄L) with
EC1. MICs are: CT 1 mg ⁄L, CTL
>1 mg ⁄L, PM 1 mg ⁄L, PML
0.75 mg ⁄L. (f) ESBL Etests on agar
containing cloxacillin (200 mg ⁄L)
with EC2. MICs are: CT >16 mg ⁄L,
CTL >1 mg ⁄L, PM 12 mg ⁄L, PML
1 mg ⁄L.
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illustrated in Fig. 4d, where the ESBL Etests on
Mueller–Hinton agar indicated out-of-range MIC
values, whereas those on cloxacillin-containing
agar (Fig. 4e) were in range, with a further
signiﬁcant reduction in the presence of clavula-
nate (ratio MIC cefepime ⁄MIC cefepime–clavula-
nate ‡8).
Another example of using cloxacillin-contain-
ing agar is given in Fig. 6, showing two E. cloacae
strains isolated from the same sample, both of
which stably overproduce a cephalosporinase, but
only one of which also produces an ESBL. No
clear synergy was detected for either strain in
the conventional DDST (Fig. 6a, b). For the
(a)
(b) (c)
(e)(d)Fig. 7. Combination of several tests
for extended-spectrum b-lactamase
(ESBL) detection with a non-ESBL-
producing Citrobacter freundii strain
resistant to third-generation cepha-
losporins through stable AmpC
overproduction. (a) Negative dou-
ble-disk synergy test (DDST) on
Mueller–Hinton (MH) agar. (b) Neg-
ative DDST despite using narrowed
distances (<30 mm) on MH agar. (c)
Negative DDST despite using nar-
rowed distances on cloxacillin-con-
taining agar (200 mg ⁄L). (d)
Negative ESBL Etests with cefotax-
ime (CT ⁄CTL, right strip) or cefe-
pime (PM ⁄PML, left strip) on
conventional MH agar. (e) Negative
ESBL Etests with cefotaxime
(CT ⁄CTL, right strip) or cefepime
(PM ⁄PML, left strip) despite using
cloxacillin-containing agar.
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ESBL-producing strain, MICs for cephalosporins
fell outside the range of the ESBL Etests for both
CT ⁄CTL and PM ⁄PML (Fig. 6d). In contrast, the
PM ⁄PML test is positive (MIC ratios ‡8) on
cloxacillin-containing agar (Fig. 6f). For the
ESBL-non-producing strain, ESBL Etests were
not interpretable for either PM ⁄PML or CT ⁄CTL
(Fig. 6c). Both tests were negative on cloxacillin-
containing agar (Fig. 6e).
The DDST remains clearly negative, despite
any modiﬁcation, for non-ESBL strains overpro-
ducing cephalosporinase, as illustrated in Fig. 7
for a non-ESBL-producing C. freundii isolate resis-
tant to third-generation cephalosporins through
stable overproduction of its cephalosporinase. As
shown in Fig. 7a, the disk test does not show any
clavulanate synergy even when performed with
narrowed disk spacing (Fig. 7b), or on cloxacillin-
containing agar (Fig. 7c). Similar results (i.e., no
synergy) were obtained with ESBL Etests per-
formed on standard and cloxacillin-containing
media (Fig. 7d, e). Another example of a negative
DDST for a K. pneumoniae clinical isolate produc-
ing the plasmid-encoded class C cephalosporin-
ase DHA-1 is given in Fig. 8. No synergy is
detected, either with the DDST on conventional
Mueller–Hinton agar (Fig. 8a), or with narrowed
distances between the disks (Fig. 8b). Rather, the
inhibition zones around the cefotaxime or ceftaz-
idime disks are ﬂattened on the side facing the
clavulanate-containing disk, when the distances
between the disks are shortened, indicating an
antagonism related to the induction of the DHA
class C cephalosporinase by clavulanate, as pre-
viously reported [31].
Adaptation of ESBL tests when the enzyme
is not inhibited, or poorly inhibited, by
clavulanate
In some cases, strains are resistant to third-gen-
eration cephalosporins through the production of
metallo-b-lactamases (MBLs). These Ambler
class B enzymes (IMP, VIM, GIM and SPM-1)
have been isolated from Pseudomonas spp., Aci-
netobacter spp. and Enterobacteriaceae strains.
They generally hydrolyse third-generation ceph-
alosporins as well as carbapenems, but not az-
treonam. The level of carbapenem resistance
caused by MBLs is generally higher in Pseudomo-
nas spp. than in Enterobacteriaceae, which often
appear sensitive to imipenem. Walsh et al. [32]
proposed an identiﬁcation procedure for MBLs
based on the analysis of MICs. P. aeruginosa,
Acinetobacter spp. and Enterobacteriaceae may be
considered as potential MBL producers when the
imipenem MIC reaches at least 16, 8 and 2 mg ⁄L,
respectively. For a routine approach in clinical
laboratories, Walsh et al. then recommended use
of the Etest MBL, a two-sided strip containing
gradients of imipenem alone on one side, and
combined with EDTA on the other side. This test
is considered as positive when the MIC of
imipenem is reduced by at least three doubling
dilutions in the presence of EDTA [33]. However,
because false-negative results can arise for the
(a) (b)
Fig. 8. Combination of several tests for extended-spectrum b-lactamase (ESBL) detection in a Klebsiella pneumoniae strain
resistant to third-generation cephalosporins owing to production of an inducible DHA-1 class C b-lactamase. (a) Negative
double-disk synergy test (DDST) on Mueller–Hinton (MH) agar. (b) Negative DDST despite using narrowed distances
(<30 mm) on conventional MH agar. Arrows indicate ﬂattening of inhibition zones, indicating antagonism attributable to
the induction of the DHA-1 b-lactamase by clavulanate.
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Etest MBL with Enterobacteriaceae, a disk-diffu-
sion test based on the detection of a synergy
between a substrate-containing disk (imipenem,
ceftazidime or meropenem) and a disk containing
an MBL inhibitor (EDTA or mercaptopropionic
acid) is recommended in addition [34,35]. MBLs
may be co-produced with ESBLs, thus leading to
difﬁculties in identifying the production of each
enzyme. In a recent study, Kassis-Chikhani et al.
[36] reported the detection of a multidrug-resis-
tant K. pneumoniae strain producing both the VIM-
1 MBL and the SHV-5 ESBL in a French hospital
(Fig. 9). The MBL was detected with the EDTA
disk-diffusion test when EDTA (4 lL of a 0.5 M
solution at pH 8) was added to the imipenem disk
(Fig. 9b) as well as with the MBL Etest (Fig. 9c).
However, production of MBL enzyme alone could
not explain the high level of resistance to aztreo-
nam observed for this strain (Fig. 9a). The addi-
tion of EDTA to a clavulanate-containing disk
made it possible to demonstrate the production of
ESBL by showing synergy between EDTA-clavul-
anate and a third-generation cephalosporin or
cefepime (Fig. 9d). PCR-based screening ﬁnally
allowed the detection of the class A ESBL.
In addition to the production of class A ESBLs,
clinical isolates may be resistant to third-genera-
tion cephalosporins through the production of
extended-spectrum Ambler class D oxacillinases.
Most of these enzymes are point mutants derived
(a)
(b) (d)
(c)
Fig. 9. Detection of an extended-
spectrum b-lactamase (ESBL) (SHV-
5) in a strain of Klebsiella pneumoniae
producing the metallo-b-lactamase
VIM-1. (a) Negative double-disk
synergy test (DDST) on Mueller–
Hinton agar. (b) Positive EDTA syn-
ergy test showing the production of
a metallo-b-lactamase. (c) Positive
MBL Etest. (d) Negative conven-
tional DDST (top) and positive mod-
iﬁed DDST (bottom), showing
synergy between the disks contain-
ing ceftazidime or cefepime and a
disk containing clavulanate and
EDTA (4 lL of a 0.5 M solution
buffered at pH 8).
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from OXA-2 and OXA-10 b-lactamases. They
confer resistance to ceftriaxone, cefepime, cefpi-
rome and, especially, ceftazidime, whereas the
cefotaxime MIC is marginally increased [37]. In
contrast, OXA-17, which is an OXA-10 derivative,
is characterised by an activity against cefotaxime
that is signiﬁcantly higher than that against
ceftazidime [38]. Unlike class A ESBLs, OXA-type
ESBLs are only weakly inhibited by clavulanic
acid, except for OXA-18, and are not inhibited by
EDTA. Consequently, most remain almost un-
identiﬁable according to simple inhibition tests
[37].
ESBL DETECTION IN THE FUTURE
Despite all the methods developed during the last
two decades, the identiﬁcation of ESBLs by
conventional phenotypic methods remains some-
times difﬁcult in practice, and becomes more so as
ESBLs are more and more frequently associated
with overproduced cephalosporinases, broad-
spectrum b-lactamases (TEM-1, TEM-2, SHV-1,
SHV-11, etc.) or MBLs. Enzymic mechanisms of
resistance, including ESBLs, can also be associ-
ated with an outer-membrane permeability defect
or an efﬂux mechanism, complicating further the
interpretation of susceptibility data. Conse-
quently, molecular detection and identiﬁcation
of b-lactamases would be essential for a reliable
epidemiological investigation of antimicrobial
resistance. Molecular detection is usually based
on ampliﬁcation by PCR, followed by sequencing,
which relies on the use of speciﬁc primers,
allowing the ampliﬁcation of family or group
members. Because b-lactamases are characterised
by a wide genetic diversity, an exhaustive enzyme
characterisation using a PCR approach can be
time-consuming, and a microarray approach
would be of great help in detecting simulta-
neously several enzyme-encoding genes from a
single strain. Two approaches have already been
described: the ﬁrst for detection at the family level
[39], and the second for the identiﬁcation of the
ESBL mutants of TEM-1[40].
CONCLUSION
Because resistance to broad-spectrum b-lactams is
linked to various molecular mechanisms involv-
ing a wide variety of enzymes, ESBL detection has
become a diagnostic challenge in clinical labora-
tories. In most cases, the standard disk diffusion
tests are effective, and they are still recommended
for ESBL detection in routine laboratories. Nev-
ertheless, it is often worth combining the standard
disk diffusion test with other approaches, such as
modiﬁed disk tests or Etests, especially for those
species of Enterobacteriaceae where AmpC ceph-
alosporinase hyperproduction is likely.
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